Study Sheds Light on How Allergy Immunotherapy Provides Relief for Patients

Each year, about 2.6 million Americans receive allergy immunotherapy, widely known as allergy shots. These well-established treatments are recognized as generally safe and effective ways to reduce allergic reactions to triggers such as peanuts, bees, pollen, and cockroaches. Despite their effectiveness, much about the underlying immune mechanisms has remained unclear—especially regarding which immune cells are most important and how different doses impact treatment outcomes.

New research at the La Jolla Institute for Immunology is addressing these questions by closely analyzing how allergy immunotherapy interacts with the immune system, specifically focusing on T cells that drive allergic reactions. According to Alessandro Sette, senior author on the study published in The Journal of Allergy and Clinical Immunology, “The good thing is that allergy immunotherapies work, but we need to go deeper and characterize immune responses to allergen immunotherapies.”

To investigate the fundamentals of allergy immunotherapy, Sette and his colleagues examined how children with cockroach allergies respond to these treatments. Cockroach allergies are common in urban and under-resourced areas, where approximately 89 percent of homes show some level of cockroach allergen, and young children are particularly susceptible to severe allergic asthma attacks due to exposure.

In their study, the researchers explored the effects of allergy shots—composed of cockroach protein extracts—on T cell responses in children aged 8 to 17. Importantly, these extracts vary in their preparation and concentration levels. The team questioned whether higher or lower doses of allergen might produce different immune responses in patients.

Surprisingly, the results showed no significant difference in T cell response to allergens present in high versus low concentrations in the extracts. Sette explained, “A little goes a long way," meaning the precise amount is less critical as long as the key proteins are included. This consistency also means that allergy shots tend to have predictable effects regardless of the extract’s concentration.

The study further identified a specific type of T cell, called Th2 cells, as the main target for allergy immunotherapy. These cells are believed to play a central role in developing allergies and asthma. By desensitizing Th2 cells, allergy shots can dampen the severity of allergic symptoms.

The researchers also compared the therapy's effectiveness for children with both strong and weak allergic responses to cockroach allergens. They found immunotherapy was effective across the board, regardless of the initial severity of allergy. As Sette notes, even those with intense allergies benefited from treatment, debunking fears that extreme sensitivity would limit improvement.

Moving forward, the team plans to investigate other T cell subtypes and analyze gene expression to further understand which cells are impacted during therapy. "This research may open the road to developing immunotherapies that aren't based on crude extracts but are much more defined on a molecular level," explains Ricardo Da Silva Antunes, first author of the study.